Stephen is a founding partner of Brandon Capital Partners. Previously Stephen worked with Bio Innovation SA and helped establish Terra Rossa Capital, a dedicated life science Fund Manager in Adelaide.
Prior to this Stephen was a Director of Apax Partners a leading international private equity group based in London. During this time he was also a Director of Imperial Innovations, the commercialisation company of Imperial College London. Before joining Apax Partners, he fulfilled roles in product development with UK biotechnology company Cantab Pharmaceuticals. Earlier, Stephen spent ten years as a research immunologist in London and California.
Stephen is a Director of Elastagen P/L, MiReven P/L, Vaxxas P/L, Helmedix P/L and the Cancer Therapeutics CRC. Stephen has an Honours degree in Immunology and Biochemistry, a PhD in Immunology from Kings College London and an MBA, specialising in Entrepreneurship, from Imperial College London. Stephen is a Graduate of the Australian Institute of Company Directors and a member of AusBiotech.